Novo Nordisk A/S

Research Novo Nordisk A/S (NOVO-B) on Bullrun: valuation model: 19.3% undervalued, market cap DKK 1.39T, P/E 11.5, dividend yield 5.0%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNOVO-B
• ExchangeCO
• CountryDenmark
• SectorHealthcare
• IndustryDrug Manufacturers - General
• CurrencyDKK
• Valuation signal19.3% undervalued
• Market capDKK 1.39T
• P/E11.5
• Dividend yield5.0%
• Financial periodFY2025
• RevenueDKK 309.06B
• Revenue growth6.4%
• Net incomeDKK 102.43B
• Free cash flowDKK 58.96B
• Gross margin81.0%

Valuation Snapshot

Bullrun's latest valuation model marks Novo Nordisk A/S as 19.3% undervalued; latest market cap is DKK 1.39T; P/E is 11.5; dividend yield is 5.0%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.

Frequently asked questions

Is Novo Nordisk A/S overvalued or undervalued?

Bullrun's valuation model currently marks Novo Nordisk A/S as 19.3% undervalued.

What is Novo Nordisk A/S's market cap?

Novo Nordisk A/S's market capitalization is DKK 1.39T.

What is Novo Nordisk A/S's P/E ratio?

Novo Nordisk A/S's price-to-earnings (P/E) ratio is 11.5.

Does Novo Nordisk A/S pay a dividend?

Novo Nordisk A/S has a dividend yield of 5.0%.

What does Novo Nordisk A/S do?

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.